Inventiva SACA

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

01 أبريل 2025 17:00:00 بحسب Nasdaq GlobeNewswire

Inventiva reports its 2024 full year results and provides a business update

26 مارس 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

19 مارس 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

26 فبراير 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

20 فبراير 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

10 فبراير 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology

29 يناير 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

24 يناير 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025

22 يناير 2025 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference

17 ديسمبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million

16 ديسمبر 2024 02:30:00 بحسب Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024

12 ديسمبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva reports 2024 Third Quarter Financial Information¹

21 نوفمبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024  

20 نوفمبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Combined General Meeting of December 11, 2024 - Availability of the preparatory documents

20 نوفمبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

15 نوفمبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH

30 أكتوبر 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024

21 أكتوبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants

14 أكتوبر 2024 13:45:00 بحسب Nasdaq GlobeNewswire

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

14 أكتوبر 2024 02:35:00 بحسب Nasdaq GlobeNewswire